Abstract
Canine atopic dermatitis is an inflammatory and pruritic skin disease, with clinical characteristics associated with IgE antibodies, most commonly directed against environmental allergens which impact the quality of life in affected animals and their owners. Treatment is multifaceted and must be adapted to each patient individually. Currently, a medication based on caninized monoclonal antibody (mAb), called lokivetmab, has shown promise for controlling the signs of the disease, as it neutralizes interleukin IL-31, a cytokine that plays an important role in the pathogenesis of atopy. The impact of dermatological diseases in the life of the dog and its owner has only been studied in recent years through validated questionnaires. This additional measurement tool is important for evaluating the therapeutic success of interventions in atopic dermatitis, as clinical improvement may not correlate with an increased quality of life. This study aimed to evaluate the quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapy. Ten atopic dogs treated at the dermatology service of the Veterinary Hospital of the Veterinary School from UFMG were selected. Quality of life was assessed using a validated questionnaire, before and after lokivetmab therapy. It concludes that treatment with lokivetmab significantly improved the quality of life of dogs with atopic dermatitis and their owners.
Highlights
Atopic dermatitis (AD) is an extremely common, pruritic, and frustrating disease to treat (Marsella & De Benedetto, 2017)
The findings in the clinical, histological, immunological, and epidemiological aspects of this dermatopathy led to the definition of canine atopic dermatitis (CAD) as an inflammatory and pruritic skin disease, with clinical characteristics associated with immunoglobulin E (IgE) antibodies, more commonly directed against environmental allergens (Halliwell, 2006) and that impacts the quality of life (QoL) of affected animals and, of their owners (Linek & Favrot, 2010)
The hypothesis of the present study considers that atopic dogs and their owners have a higher QoL after therapy with lokivetmab
Summary
Atopic dermatitis (AD) is an extremely common, pruritic, and frustrating disease to treat (Marsella & De Benedetto, 2017). The findings in the clinical, histological, immunological, and epidemiological aspects of this dermatopathy led to the definition of canine atopic dermatitis (CAD) as an inflammatory and pruritic skin disease, with clinical characteristics associated with immunoglobulin E (IgE) antibodies, more commonly directed against environmental allergens (Halliwell, 2006) and that impacts the quality of life (QoL) of affected animals and, of their owners (Linek & Favrot, 2010). The most common clinical sign is pruritus, which precedes other signs and is responsive to the use of corticosteroids (Favrot, Steffan, Seewald & Picco, 2010a; Bruet, Bourdeau, Roussel, Imparato & Desfontis, 2012). The QoL of both, dogs and owners, must be considered (Medeiros, 2017)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
